Partially Evoked Epithelial-Mesenchymal Transition (EMT) Is Associated with Increased TGFβ Signaling within Lesional Scleroderma Skin
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The origin of myofibroblasts in fibrotic conditions remains unknown and in systemic sclerosis (SSc) it has been proposed that activation of local fibroblasts, trans-differentiation of perivascular or vascular cells, recruitment of fibrocyte progenitors, or epithelial to mesenchymal transition (EMT) could be contributing. Data from our laboratory indicate that the epidermis in scleroderma is activated with the keratinocytes exhibiting a phenotype normally associated with tissue repair, including phosphorylation profiles indicative of TGFβ signaling. Since TGFβ is a known inducer of EMT, we investigated if there is evidence of this process in the SSc epidermis. In order to validate antibodies and primers, EMT was modeled in HaCaT cells cultured in the presence of TGFβ1. Skin sections were stained with phosho-SMAD2/3, as well as with epithelial and mesenchymal markers. Moreover, mRNA levels of transcription factors associated with EMT were studied in epidermal blister sheets. We observed critical changes in the scleroderma epidermis; showing significantly increased nuclear translocation of phosphorylated Smad2/3, consistent with active TGFβ signaling in SSc keratinocytes. While profound EMT could be induced in keratinocytes in vitro with the appearance of SNAI1/2 and FSP-1, and an accompanying loss of E-cadherin, in the scleroderma skin active TGFβ signaling was accompanied by only partial EMT-like changes characterised by induction of SNAI1 alone and with no loss of E-cadherin. Together, our findings support a model of altered differentiation and TGFβ dependent activation of scleroderma epithelial cells leading to a partially evoked EMT like process in the fibrotic skin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In SSc skin, expression of the key EMT inducing transcription factor SNAI1 can be observed in keratinocytes, but not loss of their epithelial E-Cadherin marker (96).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [96]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Deficient Smad7 expression: A putative molecular defect in scleroderma
Dong, C., Zhu, S., Wang, T., Yoon, W., Li, Z., Alvarez, R. J., ten Dijke, P., White, B., Wigley, F. M., & Goldschmidt-Clermont, P. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062010399 · Cited by 244 · cited 1×
“Enhanced TGFβ1 and TGFβ receptor expression and active TGFβ signaling in SSc skin is well documented [7,8].”
BackgroundRetractedAnalysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · cited 1×
“Sequences of primers used in a study are listed below: TUBB Forward: ACATACCTTGAGGCGAGCAA Reverse: TCACTGATCACCTCCCAGAA SNAI1 Forward: CAGGACTCTAATCCAGAGTTTACCT Reverse: ACAGAGTCCCAGATGAGCATTG SNAI2 Forward: GAACTGGACACACATACAGTGAT Reverse: GGTAGTCCACACAGTGATGG Target transcript expression were normalised to the expre…”
MethodAletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27584 · Cited by 9,619
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 1×
“Snail family proteins are direct targets of TGFβ in epithelial cells and have a critical role in EMT during development, in carcinogenesis, and in tissue repair [23].”
BackgroundScleroderma (systemic sclerosis): classification, subsets and pathogenesis
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-95 · Cited by 3,950
Cano, A., Pérez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., Portillo, F., & Nieto, M. A. (2000) · Nature Cell Biology · doi:10.1038/35000025 · Cited by 3,668 · cited 1×
“In addition, to determine whether active Smad dependent TGFβ signaling is stimulating SSc keratinocytes in vivo to undergo EMT, transcription factors critically associated with the transition, SNAI1 and SNAI2 were studied in the epidermal blister sheets [14,15].”
Backgroundvan den Hoogen, F., Khanna, D., Fransen, J., Johnson, S. R., Baron, M., Tyndall, A., Matucci‐Cerinic, M., Naden, R. P., Medsger, T. A., Carreira, P. E., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.38098 · Cited by 3,409
Self-citationMassagué, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3434 · Cited by 3,128
TGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804
TGF-β and epithelial-to-mesenchymal transitions
Zavadil, J., & Böttinger, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208927 · Cited by 1,578
Cited by
TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis
Hao, Y., Baker, D., & ten Dijke, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112767 · Cited by 1,142
Transforming growth factor beta (TGF‐β) isoforms in wound healing and fibrosis
Lichtman, M. K., Otero‐Vinas, M., & Falanga, V. (2016) · Wound Repair and Regeneration · doi:10.1111/wrr.12398 · Cited by 626
Epithelial-mesenchymal transition in tissue repair and fibrosis
Stone, R. C., Pastar, I., Ojeh, N., Chen, V., Liu, S., Garzon, K. I., & Tomic-Canic, M. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2464-0 · Cited by 572
“To begin with, HGF can regulate master EMT transcription factor SNAIL1 (which decreases Ecadherin ) and Slug (which decreases desmoplakins) aiding the breakdown of intercellular adhesions (Grotegut et al. 2006; Savagner et al. 1997).”
BackgroundInfluentialPathophysiology of systemic sclerosis (scleroderma)
Rosendahl, A., Schönborn, K., & Krieg, T. (2022) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12505 · Cited by 160
Unraveling SSc Pathophysiology; The Myofibroblast
van Caam, A., Vonk, M., van den Hoogen, F., van Lent, P., & van der Kraan, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02452 · Cited by 153
The Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrotic Disorders
Di Gregorio, J., Robuffo, I., Spalletta, S., Giambuzzi, G., De Iuliis, V., Toniato, E., Martinotti, S., Conti, P., & Flati, V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.607483 · Cited by 145
“The EMT model was reproduced in a SSc keratinocyte cell line, under TGF-β stimulus, and a partial EMT-like process, without E-cadherin loss, was observed (Nikitorowicz-Buniak et al., 2015).”
BackgroundAsano, Y. (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.14153 · Cited by 146
Asano, Y. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092687 · Cited by 155
“These myofibroblasts originate from resident fibroblasts, bone marrow-derived fibrocytes [91], epithelial-to-mesenchymal transition [92], EndoMT [46,47] and adipocyte-to-myofibroblast transdifferentiation [93].”
BackgroundThuan, D. T. B., Zayed, H., Eid, A. H., Abou-Saleh, H., Nasrallah, G. K., Mangoni, A. A., & Pintus, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01985 · Cited by 122
TRPV 4 regulates matrix stiffness and TGF β1‐induced epithelial‐mesenchymal transition
Sharma, S., Goswami, R., Zhang, D. X., & Rahaman, S. O. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13972 · Cited by 108
“have recently been demonstrated, indicating a link between EMT and skin fibrosis and oncogenesis.(15-19) Mechanical cues, for example,”
BackgroundMaria, A. T. J., Partouche, L., Goulabchand, R., Rivière, S., Rozier, P., Bourgier, C., Quellec, A. L., Morel, J., Noël, D., & Guilpain, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03112 · Cited by 106
“On the other hand, EMT also represents a potential mechanism in SSc, where epidermal cells may acquire mesenchymal and fibroblastic features under the activation of TGF-beta signaling pathway within lesional skin, further increasing the fibrotic burden (76).”
BackgroundCTGF Loaded Electrospun Dual Porous Core-Shell Membrane For Diabetic Wound Healing
Augustine, R., Zahid, A. A., Hasan, A., Wang, M., & Webster, T. J. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s224047 · Cited by 101
“72 In order to promote cell migration in keratinocytes, tight cell-cell adhesion of keratinocytes should be disrupted with appropriate cues; 73 such signals (mostly growth factors and chemokines) can induce epithelial-mesenchymal transition (EMT) of keratinocytes which facilitate their migration…”
Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma
Takahashi, T., Asano, Y., Sugawara, K., Yamashita, T., Nakamura, K., Saigusa, R., Ichimura, Y., Toyama, T., Taniguchi, T., Akamata, K., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160247 · Cited by 91
“Primers amplifying the specific promoter regions of the SNAI1 and AIRE genes were used.”
BackgroundInfluentialHahn, J. M., McFarland, K. L., Combs, K. A., & Supp, D. M. (2016) · Burns & Trauma · doi:10.1186/s41038-016-0055-7 · Cited by 86
Morphological and cytoskeleton changes in cells after EMT
Nurmagambetova, A., Mustyatsa, V. V., Saidova, A. A., & Vorobjev, I. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-48279-y · Cited by 73
“Alteration of growth of MTs, in turn, could be explained by increased expression of β-tubulin III after EMT described elsewhere 33–36 and confirmed in our study (Supplementary Fig.”
ResultTissue transglutaminase: a multifunctional and multisite regulator in health and disease
Yao, Z., Fan, Y., Lin, L., Kellems, R. E., & Xia, Y. (2023) · Physiological Reviews · doi:10.1152/physrev.00003.2023 · Cited by 65
Involvement of Epithelial-Mesenchymal Transition (EMT) in Autoimmune Diseases
Sarrand, J., & Soyfoo, M. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914481 · Cited by 52
The role of adipokines in systemic sclerosis: a missing link?
Żółkiewicz, J., Stochmal, A., & Rudnicka, L. (2019) · Archives of Dermatological Research · doi:10.1007/s00403-019-01893-1 · Cited by 53
“Partial EMT-like changes may contribute to fibrosis in the skin of patients with SSc [86].”
BackgroundSharma, S., Goswami, R., & Rahaman, S. O. (2018) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-018-00565-w · Cited by 50
IL-17A Dissociates Inflammation from Fibrogenesis in Systemic Sclerosis
Dufour, A. M., Borowczyk, J., Alvarez, M., Truchetet, M., Modarressi, A., Brembilla, N. C., & Chizzolini, C. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.05.026 · Cited by 46
“…was shown to be abnormally differentiated (Nikitorowicz-Buniak et al., 2014), with active transforming growth factor-b 1 (TGF-b) signaling (Nikitorowicz-Buniak et al., 2015) consistent with a wound healing phenotype (Aden et al., 2008), enhancing the contraction of fibroblastpopulated…”
BackgroundInfluentialVascular Remodelling and Mesenchymal Transition in Systemic Sclerosis
Nicolosi, P. A., Tombetti, E., Maugeri, N., Rovere, P. Q., Brunelli, S., & Manfredi, A. A. (2016) · Stem Cells International · doi:10.1155/2016/4636859 · Cited by 47
Solé, C., Giménez‐Barcons, M., Fábrega, B. F., Ordi‐Ros, J., & Cortés-Hernández, J. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14539 · Cited by 43
The contribution of mesenchymal transitions to the pathogenesis of systemic sclerosis
Rosa, I., Romano, E., Fioretto, B. S., & Manetti, M. (2020) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2019.19081 · Cited by 44
“In another study, the lesional SSc epidermis has been reported to exhibit an increased amount of TGF-β signaling and Snail1-encoding gene (SNAI1) expression (39).”
BackgroundFan, Q., Liang, X., Xu, Z., Li, S., Han, S., Xiao, Y., Xu, Q., Yuan, R., Yang, S., & Gao, H. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154884 · Cited by 39
Taki, Z., Gostjeva, E. V., Thilly, W. G., Yaseen, B., Lopez, H., Mirza, M., Hassuji, Z., Vigneswaran, S., Abdi, B. A., Hart, A., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41267 · Cited by 41
Self-citationRecent advances in mouse models for systemic sclerosis
Yue, X., Yu, X., Petersen, F., & Riemekasten, G. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.06.013 · Cited by 44
A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways
Jiménez, S. A., Mendoza, F. A., & Piera-Velázquez, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1551911 · Cited by 43
Corallo, C., Cutolo, M., Volpi, N., Franci, D., Aglianò, M., Montella, A., Chirico, C., Gonnelli, S., Nuti, R., & Giordano, N. G. (2016) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x16671928 · Cited by 35
Ono, R., Watanabe, T., Kawakami, E., Iwasaki, M., Tomizawa-Murasawa, M., Matsuda, M., Najima, Y., Takagi, S., Fujiki, S., Sato, R., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.001 · Cited by 35
The Rationale for Targeting the JAK/STAT Pathway in Scleroderma-Associated Interstitial Lung Disease
Talotta, R. (2020) · Immunotherapy · doi:10.2217/imt-2020-0270 · Cited by 33
New Proposal to Define the Fascial System
Bordoni, B., Marelli, F., Morabito, B., Castagna, R., Sacconi, B., & Mazzucco, P. (2018) · Complementary Medicine Research · doi:10.1159/000486238 · Cited by 33
Emerging diagnostic and therapeutic challenges for skin fibrosis in systemic sclerosis
Abraham, D., Lescoat, A., & Stratton, R. J. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101252 · Cited by 30
Self-citationRecent advances in animal models of systemic sclerosis
Asano, Y. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13185 · Cited by 27
The Effects of Anti-TGF-β1 on Epithelial–Mesenchymal Transition in the Pathogenesis of Adenomyosis
Kay, N., Huang, C., Shiu, L., Yu, Y.-C., Chang, Y., Suen, J., Tsai, E., & Huang, S.-T. J. (2020) · Reproductive Sciences · doi:10.1007/s43032-020-00139-0 · Cited by 27
“In the studies using TGF-β1-suppressing agents to treat systemic sclerosis [54] as well as renal and pulmonary fibrosis [43, 44, 53] or other agents to treat adenomyosis and pulmonary fibrosis [23, 55–58], intraperitoneal injection and oral gavage were respectively chosen as routes of delivery.”
MethodSaigusa, R., Yamashita, T., Miura, S., Hirabayashi, M., Nakamura, K., Miyagawa, T., Fukui, Y., Yoshizaki, A., Sato, S., & Asano, Y. (2019) · Experimental Dermatology · doi:10.1111/exd.13900 · Cited by 23
The Role of Pro-fibrotic Myofibroblasts in Systemic Sclerosis: From Origin to Therapeutic Targeting
Romano, E., Rosa, I., Fioretto, B. S., Matucci‐Cerinic, M., & Manetti, M. (2021) · Current Molecular Medicine · doi:10.2174/0929867328666210325102749 · Cited by 26
Single cell meta-analysis of EndMT and EMT state in COVID-19
Zhang, L., Tang, C., Zhang, M., Tong, X., Xie, Y., Yan, R., Wang, X., Zhang, X., Liu, D., & Li, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.976512 · Cited by 24
COX2 is induced in the ovarian epithelium during ovulatory wound repair and promotes cell survival†
Carter, L. E., Cook, D. P., Collins, O. M., Gamwell, L. F., Dempster, H. A., Wong, H. W., McCloskey, C. W., Garson, K., Vuong, N., & Vanderhyden, B. C. (2019) · Biology of Reproduction · doi:10.1093/biolre/ioz134 · Cited by 25
Chemokines in systemic sclerosis
King, J., Abraham, D., & Stratton, R. J. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.12.001 · Cited by 22
“…myofibroblasts and other myofibroblast precursor cells derived from circulating monocytes (fibrocytes) as well as cells undergoing EndoMT and possibly EMT are drawn into the fibrotic lesions(Postlethwaite et al., 2004, Nikitorowicz-Buniak et al., 2015, Good et al., 2015, Mathai et al., 2010).”
BackgroundSelf-citationNollet, M., Bachelier, R., Joshkon, A., Traboulsi, W., Mahieux, A., Moyon, A., Muller, A., Somasundaram, I., Simoncini, S., Peiretti, F., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42063 · Cited by 17
“Of interest, EMT has been shown to participate in the pathogenesis of SSc (38).”
BackgroundIguratimod inhibits skin fibrosis by regulating TGF‐β1/Smad signalling pathway in systemic sclerosis
Xie, X., Gan, H., Tian, J., Li, F., Chen, J., Wang, J., Liao, J., & Li, S. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13791 · Cited by 17
The compound LG283 inhibits bleomycin-induced skin fibrosis via antagonizing TGF-β signaling
Utsunomiya, A., Chino, T., Kasamatsu, H., Hasegawa, T., Utsunomiya, N., Luong, V. H., Matsushita, T., Sasaki, Y., Ogura, D., Niwa, S., et al. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02773-2 · Cited by 21
“LG283 was designed and synthesized as one of a series of curcumin derivatives with the original name of PE859 (3-[(1E)-2-(1H-indol-6-yl)ethenyl]-5-[(1E)-2-[2-methoxy-4-(2-pyridylmethoxy) phenyl] ethenyl]-1H-pyrazole) by Okuda and Sugimoto et al.”
BackgroundInfluentialSystemic sclerosis: Is the epithelium a missing piece of the pathogenic puzzle?
Asano, Y., Takahashi, T., & Saigusa, R. (2019) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.04.007 · Cited by 19
Sirtuins and Hypoxia in EMT Control
Aventaggiato, M., Barreca, F., Sansone, L., Pellegrini, L., Russo, M. A., Cordani, M., & Tafani, M. (2022) · Pharmaceuticals · doi:10.3390/ph15060737 · Cited by 20
“However, in cancer cells, the upregulation of SNAIL1 inhibits miR-34 expression, inducing EMT [108].”
BackgroundInfluentialTAGLIARI, E., Campos, L. F., Casagrande, T. A. C., Fuchs, T., de Noronha, L., & Campos, A. C. L. (2021) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.2216 · Cited by 15
Karve, K., Netherton, S. J., Deng, L., Bonni, A., & Bonni, S. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02905-z · Cited by 14
Cancer risk in systemic sclerosis: identifying risk and managing high-risk patients
Fragoulis, G., Daoussis, D., Pagkopoulou, E., Garyfallos, A., Kitas, G. D., & Dimitroulas, T. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1847641 · Cited by 16
Menezes, T. C. F., Lee, M. H., Balladares, D. C. F., Nolan, K., Sharma, S., Kumar, R., Ferreira, E. V. M., Graham, B. B., & Oliveira, R. K. F. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.036952 · Cited by 11
Jozic, I., Chéret, J., Abujamra, B. A., Miteva, M. I., Gherardini, J., & Paus, R. (2021) · Biomedicines · doi:10.3390/biomedicines9050572 · Cited by 11
“Moreover, the suggested research focus may identify in Cav1 a promising novel target for therapeutic intervention—not only in FFA management, but also for other forms of cicatricial alopecia [94], as well as for other stem cell- and IP-related diseases such as multiple sclerosis [95] and autoimmune uveitis [96,97] and…”
BackgroundE3 ubiquitin ligase: A potential regulator in fibrosis and systemic sclerosis
Huang, X., Zhang, L., Duan, Y., Wang, Y., Zhao, J.-H., & Wang, J. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.07.003 · Cited by 10
Lobbins, M. L. B., Slominski, A. T., Hasty, K. A., Zhang, S., Miller, D. D., Li, W., Kim, T., Janjetović, Z., Tuckey, R. C., Scott, I.-S. O., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010367 · Cited by 9
Pathophysiology in Systemic Sclerosis: Current Insights and Future Perspectives
Al-Gburi, S., Moinzadeh, P., & Krieg, T. (2025) · Sclerosis · doi:10.3390/sclerosis3020017 · Cited by 11
Role of TRPV4 in matrix stiffness-induced expression of EMT-specific LncRNA
Sharma, S., Ma, L., & Rahaman, S. O. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03844-1 · Cited by 10
Cellular and Molecular Diversity in Scleroderma
Hinchcliff, M., García-Milian, R., Donato, S. D., Dill, K. E., Bundschuh, E., & Galdo, F. D. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2022.101648 · Cited by 7
Wang, F., Lyu, X. Y., Qin, Y. M., & Xie, M. J. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1375331 · Cited by 6
What can we learn from Fli1 -deficient mice, new animal models of systemic sclerosis?
Asano, Y. (2018) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198318758221 · Cited by 7
Autoantibodies Which Bind to and Activate Keratinocytes in Systemic Sclerosis
Moezinia, C. J., Wong, V., Watson, J., Nagib, L., Garces, S. L., Zhang, S., Abdi, B. A., Newton, F., Abraham, D., & Stratton, R. J. (2023) · Cells · doi:10.3390/cells12202490 · Cited by 6
Self-citationPhosphate Toxicity and Epithelial to Mesenchymal Transition
Lewis, E. M., Seltun, F., Razzaque, M. S., & He, P. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-91623-7_8 · Cited by 6
Understanding the Role of Epithelial Cells in the Pathogenesis of Systemic Sclerosis
Nagib, L., Kumar, A., & Stratton, R. J. (2025) · Cells · doi:10.3390/cells14130962 · Cited by 4
Self-citationTakahashi, T., & Asano, Y. (2025) · Sclerosis · doi:10.3390/sclerosis3020020 · Cited by 4
Zeng, L., Xie, L., Hu, J., He, C., Liu, A., Lu, X. H., & Zhou, W. (2024) · Cell Cycle · doi:10.1080/15384101.2024.2345481 · Cited by 4
“Within the scleroderma skin, there also existed a partial EMT, albeit that the underlying mechanism of this phenomenon remains to be elucidated [61].”
BackgroundCui, X., Lin, Q., Ping, H., & Liang, Y. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9253745 · Cited by 4
“Binding of TGF-β to its receptor activates Smad2 and Smad3 signaling pathways through growth differentiation factor 15 (GDF15) [31] which inhibit the transcriptional activity of E-cadherin, thereby promoting EMT [32].”
BackgroundEpithelial–mesenchymal transition in cutaneous fibrosis disease: from mechanisms to therapy
Yuan, S., Luo, Z., Yang, N., Xiong, T., Chen, Y., Jian, X., Wang, Y., Xiao, S., Chen, J., & Deng, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1834346 · Cited by 3
Evaluation of renal damage in a bleomycin-induced murine model of systemic sclerosis.
Pérez-Figueroa, D. C., Reyes-Jiménez, E., Velázquez-Enríquez, J. M., Reyes-Avendaño, I., González-García, K., Villa‐Treviño, S., Aguilar, H. T., Baltiérrez‐Hoyos, R., & Vásquez-Garzón, V. R. (2023) · PubMed Central · doi:10.22038/ijbms.2023.67117.14720 · Cited by 5
Zhang, Y., Xu, L., Chen, Q., Guan, T., Lin, N., Xu, D., Lu, L., Dai, Q., & Song, X. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6557486 · Cited by 2
“e pathogenesis of SSc-ILD has not been completely unraveled, but there is a wide belief that epithelial-mesenchymal transition (EMT) may take place in the skin of SSc patients and play a role in the pathogenesis of ILD [4, 5].”
BackgroundOrteu, C. H., & Denton, C. P. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook054 · Cited by 2
Self-citationMendoza, F. A., Piera-Velázquez, S., & Jiménez, S. A. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-026-02679-5 · Cited by 1
“…- cellular pathways, including MAPK, ERK, and NFK-β, promoting inflammation and a pro-fibrotic state through the expression of cyto - kines such as IL-6, IL-4, and IL-1 phenomenon in the development of pulmonary fibrosis that has also been demonstrated in the fibrotic skin of SSc patients [ 65].”
Novel approaches to identify biomechanisms in systemic sclerosis
Lopez, H. (2017) · UCL Discovery (University College London)
Дергилев, К. В., Цоколаева, З. И., Beloglazova, I. B., Vasilets, Y. D., Traktuev, D. O., Bn, K., & Парфенова, Е. В. (2021) · General Reanimatology · doi:10.15360/1813-9779-2021-6-49-55
“Such patients have elevated levels of IL-1, IL-17, MCP1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4 and IL8/CXCL8, accompanied by increased EMT activity, excessive fibroblast formation and fibrotic transformation of various tissues, including the heart [27, 28].”
BackgroundAwan, N. U., Fida, T., Waheed, K., Uzma Malik, F. C. P. S., Aslam, A., Mehmood, K., ul, Z., & Sadiq, S. M. (2023) · Research Square · doi:10.21203/rs.3.rs-3154595/v1
Leemon, N., Suresh, S., Najeeb, S. H., Binumon, T. M., & Sreejith, P. P. (2023) · Journal of Endocrinology & Reproduction · doi:10.18311/jer/2023/33509
Cellular and molecular dysregulation of the esophageal epithelium in systemic sclerosis
Dapas, M., Clevenger, M. H., Makinde, H. M., Therron, T., Carlson, D. A., Carns, M. A., Aren, K., Wei, C., Mian, K., Muhammad, L. N., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.195322 · Cited by 2
Metadata
- Authors
- Nikitorowicz-Buniak, J., Denton, C. P., Abraham, D., & Stratton, R.
- Affiliations
- University College London (GB)
- Corresponding author
- Stratton, Richard
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-07-28
- Volume
- 10
- Issue
- 7
- Pages
- e0134092
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4517793
- OpenAlex
- W1924940035
- Cited by
- 73
- References
- 34
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 4 · 2023: 8 · 2022: 8 · 2021: 7 · 2020: 10 · 2019: 9 · 2018: 7 · 2017: 4 · 2016: 7 · 2015: 1
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Rosetrees Trust
- Versus Arthritis (19427, 18925)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Keywords
- systemic sclerosis, epithelial-mesenchymal transition, TGF-beta signaling, keratinocytes, epidermis, myofibroblast origin, Smad2/3 phosphorylation, SNAI1, E-cadherin, skin fibrosis, HaCaT keratinocytes
- MeSH terms
- Cells, Cultured, Fluorescent Antibody Technique, Humans, Immunoenzyme Techniques, Phosphorylation, RNA, Messenger, Scleroderma, Systemic, Skin Diseases, Keratinocytes, Case-Control Studies, Reverse Transcriptase Polymerase Chain Reaction, Cell Proliferation, Transforming Growth Factor beta1, Epithelial-Mesenchymal Transition, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.